Search PubMed⌕ Search

Biomedical subjects

C Noblet

Publications and source records attributed to C Noblet.

35 records · Page 2Linked to original sources
PubMed1991

[Changes in erythrocyte deformability in Alzheimer's disease].

In a previous work we showed an alteration of erythrocyte filtration ability in patients with Alzheimer's disease according to their age and illness duration. This study has for aim to find a criteria of deformability that would be constant in all Alzheimer patients and would show a modification of red cell membranes. The erythrocyte filterability was studied in this present paper, in accord to Reid and Dormandy method using two values of depression (5 and 0 cm of water). These depressions correspond to the physiological values of blood pressure at the level of precapillary and capillary systems. The ratio between the result obtained at 5 cm and the result at 0 cm is constant in normal patient without organic disease and it is independent of age. At the opposite, this ratio increase very significantly in all Alzheimer patients, and this is not correlated to the initial value of filtrability. This ratio could be an index of the alteration of red cell membranes.

Adult↗
PubMedDate not supplied

[Hypoglycemia induced by cibenzoline in the elderly].

Hypoglycaemia induced by class IA antiarrhythmic agents has been described. A case of cibenzoline-induced hypoglycaemia with favourable outcome is reported. The patient's age (84 years), increased renal impairment and malnutrition acted as facilitating factors. Blood insulin levels were normal in both absolute and relative values. Therapeutic overdosage in relation to age and renal function has been found in 20 out of 24 cases published or recorded by the French pharmacovigilance system. The mechanism of this hypoglycaemia is uncertain; absolute or relative hyperinsulinism has been detected in only 5 out of 14 controlled cases.

Aged↗
PubMedDate not supplied

[Jean-Baptiste].

Explore the source record for details and available documents.

Abnormalities, Multiple↗
PubMedDate not supplied

[French pharmacovigilance database system: examples of utilisation].

UNLABELLED: The French drug surveillance (pharmacovigilance) system is based on a network of 31 regional centres which receive adverse drug reaction (ADR) reports from health professionals and are drug information centers. Cases are entered into a common database, with causality scores. This database contains large amounts of data, which may be used for pharmaco-epidemiological studies. As an example, all cases in which an antihypertensive drug, suspect or not, was cited were identified. ACE-inhibitor cough was also explored. RESULTS: Since 1985, > 70,000 case reports have been entered into the database. 63 per cent were reported by specialists, 20 per cent by GPs. 54 per cent came from University Hospitals, 21 per cent from private practice. The most numerous age group was 60 to 69. The overall sex ratio (F/M) was 1.28, the female preponderance being most marked at < 39 and > 70 years of age. 43 per cent took only one drug, 20 per cent two drugs, 13.4 per cent three, and 24 per cent > three drugs. The most frequently reported effects concerned the skin and appendages (15 per cent), general status and central nervous system (9.5 per cent each), platelets, liver, and GI systems (6 per cent each). Outcome was favourable in 74 per cent. Dechallenge was positive in 71 per cent, rechallence in 6 per cent. 3.4 per cent of the patients died; in 2.2 per cent death was related to a reaction. Causality assessment indicated close temporal relationship (C2 or C3) in 69 per cent of cases; in 51 per cent of cases, no other obvious cause was found. 66 per cent of the reactions were labelled when reported. The database could also be used to explore drug utilisation: as an example, we studied the age and sex distribution of reports containing antihypertensive drugs, irrespective of their possible causal role in the reaction. Antihypertensives were mentioned in 14 per cent of the reports. The age distribution was skewed towards greater age, with a maximum of 70 years. F/M was 1.57, with more M use < 20 and 30-59, whereas F were more common between 20-29 and 60 years. beta-blockers were more often associated with patients under 70, whereas above 70 diuretics and centrally acting antihypertensive drugs were more often reported. This could be related to greater use or worse tolerance of these drugs. As an example of the exploration of a specific drug-reaction relationship, we explored the relationship between the use of ACE inhibitors (ACEI) and cough. ACE inhibitors were present in 6 per cent of cases, but in 75 per cent of reports of cough. F/M was 1.29 (NS) for all reports concerning ACEI, 1.28 for cough unrelated to ACEI, 2.1 for cough with ACEI (P < 0.05). Cough was present in 12 per cent of all reports concerning ACEI. There was no clear difference between ACEI for cough or sex ratio; women cough more with ACEI. This does not seem related to greater ACEI use by women or to greater sensitivity of women to cough. The reason for this sex difference remains to be explained. There are large amounts of essentially underutilized data in drug surveillance databases. How they can or should be used remains to be validated.

Adult↗
PubMedDate not supplied

[Focus on the safety of ibuprofen at the analgesic-antipyretic dose].

Ibuprofen is a non-steroidal anti-inflammatory drug, available over the counter in most countries at analysis doses (600-1200 mg/day). After several years of such use, it would seem worthwhile to review recent safety data for this drug compared to reference analgesics. Spontaneous reporting to drug surveillance systems suggests one adverse reaction for every 5 million (UK) to 25 million (USA) 200 mg tablets sold, with one reported fatality for 0.6 to 23 billion tablets sold. During clinical and post-marketing studies, the frequency of adverse events was similar to that found with placebo or paracetamol. In a meta-analysis involving 46000 patients, the incidence of digestive events was 5 per cent, with 0.02 per cent upper GI bleeds. A prospective trial in 84000 children reported 0.007 per cent GI bleeds. Case-control studies of upper GI bleeding found odds ratios of the association with ibuprofen between 1 and 3, lower than those associated with aspirin, even at the low 'cardiovascular' doses. Other risks, such as the risk of renal failure, appear equally low. In the case of voluntary overdose, there appear to be little renal or other risk for ingested quantities below 6 g (30 tablets). Less than 1 per cent of the intoxications are rated as severe, and there have been even fewer fatalities. The favourable safety profile of ibuprofen may be related to short term use of low doses in otherwise healthy young patients, associated to a short product half-life, and may be to specific product properties. The quality of patient information may also be an important safety factor. When the safety of the drug in overdose is considered, substitution of aspirin or paracetamol, by ibuprofen, may actually reduce overall risk for the population.

Analgesics, Non-Narcotic↗